Use este identificador para citar ou linkar para este item:
http://higia.imip.org.br/handle/123456789/1048
Registro completo de metadados
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Andrade-Lima, Ana Luiza Magalhães de | - |
dc.contributor.author | Lins, Mecneide Mendes | - |
dc.contributor.author | Borborema, Maria do Céu Diniz | - |
dc.contributor.author | Matos, Ana Paula Rodrigues | - |
dc.contributor.author | Oliveira, Kaline Maria Maciel de | - |
dc.contributor.author | Mello, Maria Júlia Gonçalves | - |
dc.date.accessioned | 2024-06-12T17:15:14Z | - |
dc.date.available | 2024-06-12T17:15:14Z | - |
dc.date.issued | 2023 | - |
dc.identifier.uri | http://higia.imip.org.br/handle/123456789/1048 | - |
dc.description.abstract | Objective: The objective of this study was to evaluate the clinical evolution of coronavirus disease 2019 (COVID-19) in children and adolescents with cancer. Methods: Cohort involving patients undergoing cancer treatment, 19 years old and under, with the diagnosis of COVID-19 by real-time polymerase chain reaction, in a reference hospital, between March 2020 and November 2021. Data were collected from medical records and interviews with patients and/or guardians. The primary outcomes studied were severe/critical COVID-19 presentation, deaths from any cause and overall survival. The Cox proportional hazards multivariate regression analysis was performed to determine the risk of death. Results: Sixty-two participants were included, most (67.7%) were male, with a median age of 6.8 years. Severe/critical forms of COVID-19, observed in 24.2%, seemed to indicate that the pediatric population undergoing cancer treatment has a higher morbidity rate than the general pediatric population (8-9.2%). During follow-up (4.5-18 months), 20 patients (32.3%) completed their cancer treatment and 18 died (29%)-6 during hospitalization and 12 after discharge. In total 61.1% of deaths occurred within 63 days of a detectable real-time polymerase chain reaction. Patients with a higher risk of death presented with severe/critical COVID-19 [adjusted hazard risk (aHR): 8.51; 95% confidence interval (CI): 2.91-24.80; P < 0.00] solid tumors (aHR: 3.99; 95% CI: 1.43-11.12; P = 0.008) and diarrhea as a symptom of COVID-19 (aHR: 3.9; 95% CI: 1.23-12.73; P = 0.021). Conclusions: These findings support the impact that severe acute respiratory syndrome-associated coronavirus 2 infection has on the population of children and adolescents with cancer, not only regarding immediate severity but also in their survival rate. Further studies evaluating long-term outcomes of COVID-19 in children and adolescents with cancer should be encouraged. | pt_BR |
dc.language.iso | en | pt_BR |
dc.subject | COVID-19 | pt_BR |
dc.subject | Neoplasias | pt_BR |
dc.subject | Saúde da criança | pt_BR |
dc.title | The infection profile and survival of children and adolescents with COVID-19 undergoing cancer treatment: a cohort study. | pt_BR |
dc.higia.program | Artigos científicos colaboradores IMIP | pt_BR |
dc.higia.tipo | Artigo Científico | pt_BR |
Aparece nas coleções: | Artigos |
Arquivos associados a este item:
Arquivo | Descrição | Tamanho | Formato | |
---|---|---|---|---|
IMIP_Artigo - 017.2022-2023.pdf | 203.88 kB | Adobe PDF | Visualizar/Abrir |
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.